SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Millennium Pharmaceuticals, Inc. (MLNM)
An SI Board Since February 1997
Posts SubjectMarks Bans Symbol
3044 135 0 MLNM
Emcee:  icanpickem Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2719[CXCR4 and EGFR] >>Cancer Res. 2005 Dec 15;65(24):11392-9. Widespread Ctuck-9/30/2006
2718[CXCR4 expression increases liver and lung metastasis in a mouse model of pancretuck-9/30/2006
2717[CXCR4 versus multiple myeloma] >>Haematologica. 2006 May;91(5):605-12. Etuck-9/30/2006
2716CIBC from September 27, 2006:  On 9/26, MLNM announced an agreement to acquireidos-9/30/2006
2715Interesting article. Wonder if GENZ is making the same calculations and what numtom pope-9/29/2006
2714Careful what you wish for By Steven Syre, Globe Columnist | September 28, 200Icebrg-9/29/2006
2713Multicenter Phase II Study of Bortezomib in Patients With Relapsed or RefractoryIcebrg-9/28/2006
2712Millennium Pharmaceuticals "underweight" Thursday, September 28, 2006Icebrg-9/28/2006
2711Millennium Pharmaceuticals downgraded to "market underperform" ThursdIcebrg-9/28/2006
2710The idea is great, but based on the limited data to date I don't think aom&#keokalani'nui-9/28/2006
2709CXCR4 (Copied from Yahoo!) messages.finance.yahoo.com I am a bit excited aboutIcebrg-9/28/2006
2708Millennium's AnorMED Buyout Seen As Risky Peter Kang, 09.27.06, 7:00 PM ET Icebrg-9/28/2006
2707A Second Look: Millennium Pharma Slips The Associated Press NEW YORK — AnalystsIcebrg-9/27/2006
2706Millennium Pharmaceuticals "neutral" Wednesday, September 27, 2006 4:Icebrg-9/27/2006
2705citi: MLNM: Millennium Acquires AnorMed-MOZOBIL Complementary But Not Enough mopgcw-9/27/2006
2704Millennium Makes $515M Offer For AnorMED, Tops Genzyme By Aaron Lorenzo WashinIcebrg-9/27/2006
2703ML - neutral (we'll see whether they update to reflect ANOR) Velcade sales tom pope-9/26/2006
2702$12.55 happens to be the buyout offer plus the breakup fee to MLNM should ANOR gtuck-9/26/2006
2701ANOR trading at 12.55 - market expecting Genzyme to come back with a better offesjemmeri-9/26/2006
2700Can't find any publications showing that Velcade is synergistic with MOZOBILtuck-9/26/2006
2699Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with PlaIcebrg-9/26/2006
2698Beyond single-agent bortezomib: combination regimens in relapsed multiple myelomIcebrg-9/25/2006
2697[Cytotoxic synergy bewtween velcade and sorafenib (ONXX)] >>Mol Cancer Thtuck-9/23/2006
2696Took $1.30+ / share writing calls against my position. Now that the price has dIan@SI-9/20/2006
2695Took profit on half of position today as I've been increasing cash this weeksjemmeri-9/20/2006
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News